Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...
William Blair cut their Q2 2026 earnings per share estimates for shares of Oracle in a report issued on Tuesday, March 11th.
We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...
JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...
2d
Fintel on MSNWilliam Blair Downgrades Udemy (UDMY)Fintel reports that on March 12, 2025, William Blair downgraded their outlook for Udemy (NasdaqGS:UDMY) from Outperform to ...
Citi analysts increased their price target on Docusign to $115 from $113 and reiterated a Buy rating. “Revenue was a bit ...
William Blair analyst Tim Mulrooney maintained a Hold rating on ABM Industries (ABM – Research Report) today. The company’s shares opened today ...
The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...
The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...
Autism software provider CentralReach has been looking for a potential buyer, according to multiple sources with knowledge of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results